



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.: 09/823,886		ATTY. DOCKET NO.: C1102.70002US00	
	FILING DATE: March 30, 2001		CONFIRMATION NO.: 7558	
	APPLICANT: Martha Karen Newell et al.			
	GROUP ART UNIT: 1638		EXAMINER: Russell Kallis	
Sheet	1	of	1	

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
RK	A14	2004/00054291	A1	Rogers et al.	01-08-2004
RK	A15	2005/0042224	A1	Newell	02-24-2005
RK	A16	2005/0074882	A1	Newell	04-07-2005
RK	A17	2005/0158333	A1	Newell	07-21-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
RK	C33	BOUILLAUD, F. et al. "A sequence related to a DNA recognition element is essential for the inhibition by nucleotides of proton transport through the mitochondrial uncoupling protein," <i>The EMBO Journal</i> , Vol. 13, No. 8; pp: 1990-1997, 1994		
	C34	CLÉMENT et al., Superoxide anion is a natural inhibitor of FAS-mediated cell death. <i>EMBO J.</i> 1996 Jan 15;15(2): 216-25.		
	C35	COSSARIZZA et al., Mitochondrial modifications during rat thymocyte apoptosis: a study at the single cell level. <i>Exp Cell Res.</i> 1994 Sep; 214(1):323-30.		
✓	C36	LOBATO, M. et al. "Intracellular antibodies and challenges facing their use as therapeutic agents," <i>Trends in Molecular Medicine</i> ," Vol 9, No. 9; pp: 390-396, 2003		
RK	C37	ROCHAIX, J.D. et al. (eds.) <i>The Molecular Biology of Chloroplasts and Mitochondria in Chlamydomonas</i> , Chapt. 5; pgs. 63, 65 & 886 only; Kluwer Academic Publishers; 1998		

EXAMINER: <i>Russell Kallis</i>	DATE CONSIDERED: <i>4/12/2005</i>
------------------------------------	--------------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]